Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
NCT06438900

Investigating the Link Between Advanced Glycation End Products (AGEs) and Muscle Wasting in Sarcobesity

Led by Azienda Ospedaliero Universitaria Maggiore della Carita · Updated on 2024-08-01

195

Participants Needed

1

Research Sites

99 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study aims to explore whether a high level of AGEs (Advanced Glycation end products) derived from the diet may mediate diet-related muscle loss in Western-type diet, influencing the onset and progression of sarcopenia, predisposing to earlier and more severe metabolic consequences, including type 2 diabetes (T2D). The primary objective of the study is to investigate how the accumulation of AGEs is correlated with muscle loss in adult patients with obesity and type 2 diabetes or lipodystrophy in order to identify possible targets to mitigate the metabolic alterations caused by the Western diet (WD). Specifically, circulating AGEs levels on the skin will be evaluated and correlated with the stage of sarcopenia in a group of patients with obesity and a T2D diagnosis. Furthermore, the relationship between disease duration and AGE levels will be assessed. A secondary objective will be to analyze the clinical data obtained to identify metabolites and metabolic pathways responsible for the phenotype induced by the WD. The ultimate aim of the study is therefore to verify whether high levels of AGEs are correlated with an early and/or more pronounced onset of sarcopenia, concurrently with an increase in inflammation and oxidative stress.

CONDITIONS

Official Title

Investigating the Link Between Advanced Glycation End Products (AGEs) and Muscle Wasting in Sarcobesity

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients of both sexes
  • Adults aged 18 years and older
  • BMI compatible with obesity
  • Diagnosis of type 2 diabetes under good metabolic control (HbA1c < 7.5%) within 15 years of study entry
  • Diagnosis of lipodystrophy included in the European Consortium of Lipodystrophies (ECLip) Registry
Not Eligible

You will not qualify if you...

  • Age under 18 years
  • Secondary obesity or genetic diseases such as Prader-Willi Syndrome or Down Syndrome
  • Metabolic and endocrine disorders including Cushing's syndrome and hypothyroidism
  • Diagnosed with Inflammatory Bowel Disease (IBD) or cancer
  • Confirmed or planned pregnancy during study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

SCDU Endocrinology, AOU Ospedale Maggiore della Carità

Novara, Italy, 28100

Actively Recruiting

Loading map...

Research Team

F

Flavia Prodam, MD PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here